Übersichtsarbeit
Mechanism of action of tezepelumab (TEZSPIRE®) and clinical trial results in asthma
Folia Pharmacologica Japonica · 2024
DOI: 10.1254/fpj.23066 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Folia Pharmacologica Japonica, 2024. Verfasst von Mengxi Niu und 2 weiteren Autor:innen. Beteiligte Einrichtung: AstraZeneca K.K. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Anti-Asthmatic AgentsAsthmaHumansQuality of LifeCytokinesThymic Stromal LymphopoietinImmunoglobulin EAntibodies, Monoclonal, Humanized
Substanzen
Anti-Asthmatic AgentsCytokinesThymic Stromal LymphopoietinImmunoglobulin EtezepelumabAntibodies, Monoclonal, Humanized
Autor:innen und Institutionen
- AstraZeneca K.K.
Zitieren
APA
Niu, M., Yabuta, T., & Makita, N. (2024). Mechanism of action of tezepelumab (TEZSPIRE®) and clinical trial results in asthma. Folia Pharmacologica Japonica. https://doi.org/10.1254/fpj.23066
Vancouver
Niu M, Yabuta T, Makita N. Mechanism of action of tezepelumab (TEZSPIRE®) and clinical trial results in asthma. Folia Pharmacologica Japonica. 2024. doi:10.1254/fpj.23066
BibTeX
@article{Niu2024,
author = {Niu, Mengxi and Yabuta, Tadataka and Makita, Naoyuki},
title = {Mechanism of action of tezepelumab (TEZSPIRE®) and clinical trial results in asthma},
journal = {Folia Pharmacologica Japonica},
year = {2024},
doi = {10.1254/fpj.23066}
}
EUVIMED